GSK PLC

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

GSK

organization

Jurisdiction: GBLegal Form: B6ES

ACTIVE

LEI: 5493000HZTVUYLO1D793SIC: 2834

Also known as: GSK plc

Summary

GSK PLC (GSK) is an organization. It has 90 known subsidiaries.

SEC Filings

50 filings from SEC EDGAR

Date	Form Type	Description	Filing
2026-10-28	6-K	3RD QUARTER RESULTS	View
2026-10-26	6-K	DIRECTOR/PDMR SHAREHOLDING	View
2026-10-26	6-K	POSITIVE MO-REZ PHASE IB DATA IN OVARIAN CANCER	View
2026-10-26	6-K	JEMPERLI DATA SHOW 76% COMPLETE RESPONSE RATE	View
2026-10-26	6-K	RIS-REZ POSITIVE PH 3 OSTEOSARCOMA DATA IN CHINA	View
2026-10-21	6-K	US FDA APPROVES HIBSAGO FOR CHRONIC HEPATITIS B	View
2026-10-19	6-K	RIS-REZ POSITIVE EARLY DATA IN LUNG CANCER	View
2026-10-19	6-K	JEMPERLI APPROVED IN MSI-H/DMMR RECTAL CANCER	View
2026-10-15	6-K	DIRECTOR/PDMR SHAREHOLDING	View
2026-10-14	6-K	DIRECTOR/PDMR SHAREHOLDING	View
2026-10-13	6-K	DIRECTOR/PDMR SHAREHOLDING	View
2026-10-13	6-K	DIRECTOR/PDMR SHAREHOLDING	View
2026-10-13	S-8	S-8	View
2026-10-08	6-K	WENDY BECKER CBE - NEW DIRECTORSHIP	View
2026-10-06	6-K	ADMISSION TO TRADING	View
2026-10-01	6-K	TOTAL VOTING RIGHTS	View
2026-09-24	6-K	DIRECTOR/PDMR SHAREHOLDING	View
2026-09-22	CERT	NYSE CERTIFICATION	View
2026-09-22	6-K	DIRECTOR/PDMR SHAREHOLDING	View
2026-09-15	6-K	GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA	View
2026-09-15	8-A12B	8-A12B	View
2026-09-15	6-K	6-K	View
2026-09-14	6-K	JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC	View
2026-09-14	6-K	RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA	View
2026-09-11	6-K	DIRECTOR/PDMR SHAREHOLDING	View

1–25 of 50

1 / 2

Legal entity: GLEIF

SEC filings: SEC EDGAR

GSK PLC — Contributions, Lobbying & Contracts | Poliscope